LQTS: Difference between revisions

Jump to navigation Jump to search
1,106 bytes removed ,  25 March 2013
m
no edit summary
mNo edit summary
Line 311: Line 311:


===Medication/Other therapies:===  
===Medication/Other therapies:===  
*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolongation is visible on the ECG and also in LQTS3 patients with bradycardia-associated cardiac events <cite>congenital</cite>
*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolon
*[[ICD]] implantation in combination with beta-blockers in LQTS patients with previous cardiac arrest, cardiac [[syncope]] or [[ventricular tachycardia]] while on beta-blockers. ICDs should have pacing possibilities, because arrhythmic episodes are bradycardia-associated in LQTS type 3 and since post-shock pacing is relevant in all other LQTS types.
*Cardiac sympathetic denervation (LCSD) should be considered in the setting of beta-blocker breakthroughs, intolerance to pharmacotherapy and history of appropriate ICD therapies. Surgically, LCSD involves the resection of the lower two-third of the left stellate ganglion and the left-sided sympathetic chain at the level of T2, T3 and T4.
 
 
==References==
<biblio>
#Schwartz2001 pmid=11136691
#priori pmid=12736279
#genotype pmid=19926013
#moss pmid=17470695
#Alders pmid=20301308
#probands pmid=22042885
#QTc pmid=22083145
#LongQT pmid=20116193
#Adler pmid=22300664
#congenital pmid=15851169
#adenosine pmid=16105845
</biblio>

Navigation menu